Galera Therapeutics Inc GRTX:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/03/24 EDT
0.17quote price arrow down-0.017 (-9.1398%)
Volume
808,777
Close
0.186quote price arrow down-0.0076 (-3.9256%)
Volume
1,814,841
52 week range
0.09 - 3.59
Loading...
  • Open0.1922
  • Day High0.204
  • Day Low0.1838
  • Prev Close0.1936
  • 52 Week High3.59
  • 52 Week High Date06/13/23
  • 52 Week Low0.09
  • 52 Week Low Date10/31/23

Key Stats

  • Market Cap10.117M
  • Shares Out54.39M
  • 10 Day Average Volume0.88M
  • Dividend-
  • Dividend Yield-
  • Beta2.03
  • YTD % Change27.92

KEY STATS

  • Open0.1922
  • Day High0.204
  • Day Low0.1838
  • Prev Close0.1936
  • 52 Week High3.59
  • 52 Week High Date06/13/23
  • 52 Week Low0.09
  • 52 Week Low Date10/31/23
  • Market Cap10.117M
  • Shares Out54.39M
  • 10 Day Average Volume0.88M
  • Dividend-
  • Dividend Yield-
  • Beta2.03
  • YTD % Change27.92

RATIOS/PROFITABILITY

  • EPS (TTM)-1.42
  • P/E (TTM)-0.13
  • Fwd P/E (NTM)-0.15
  • EBITDA (TTM)-46.692M
  • ROE (TTM)-1,063.11%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-115.14%

EVENTS

  • Earnings Date05/09/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Galera Therapeutics Inc

 

Profile

MORE
Galera Therapeutics, Inc. is a biopharmaceutical company focused on developing a pipeline of novel, therapeutic candidates that have the potential to transform radiotherapy in cancer. The Company’s lead product candidate, avasopasem manganese (avasopasem), is a highly selective small molecule dismutase mimetic that the Company is developing for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients...
Michael Powell Ph.D.
Independent Chairman of the Board
J. Mel Sorensen M.D.
President, Chief Executive Officer, Director
Robert Beardsley Ph.D.
Chief Operating Officer
Christopher Degnan
Chief Financial Officer, Secretary
Address
45 Liberty Blvd., Suite 230
Malvern, PA
19355
United States

Top Peers

SYMBOLLASTCHG%CHG
ONVO
Organovo Holdings Inc
1.03+0.08+8.38%
VIRI
Virios Therapeutics Inc
0.4115-0.0097-2.3027%
IKT
Inhibikase Therapeutics Inc
1.39+0.05+3.73%
MNPR
Monopar Therapeutics Inc
0.7272+0.0672+10.1818%
ATHE
Alterity Therapeutics Ltd
2.05-0.09-4.21%